Clinical trials: Inhalation
Bronchiectasis
Inhalation Flow Rate-study
Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.
- Trial name
- NCT02563197
- Testing
- T-326 Inhaler
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Bayer
Asthma
Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic impairment and in healthy subjects following a single…
- Trial name
- NCT00419237
- Testing
- GW685698X
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT02242279
- Testing
- BEA 2180 BR, Tiotropium
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants
The primary purpose of this study is to determine the intra and extra pulmonary deposition and clearance of inhaled amikacin-loaded liposomes by gamma scintigraphy in healthy male participants.
- Trial name
- NCT05999942
- Testing
- Liposomal Amikacin for Inhalation
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Asthma
A Study of Inhaled AZD8630 in Adolescents With Asthma
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and…
- Trial name
- APkITA (NCT07065331)
- Testing
- AZD8630, Dry powder inhaler
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT00219622
- Testing
- tofimilast
- Where
- 40 sites in United States, Argentina and 4 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Lung Deposition Via Different Inhalation Devices
The purpose of this study is to assess the deposition of budesonide to the lung after inhalation with 5 different devices and to relate the findings to in vitro properties of inhaled budesonide.
- Trial name
- NCT00975754
- Testing
- Pulmicort pMDI HFA, Budesonide pMDI HFA, Pulmicort Repulses
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug…
- Trial name
- NCT01120093
- Testing
- Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid
- Where
- 11 sites in Belgium, Germany
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Viral Pneumonia, Nitric Oxide
Inhaled NO for the Treatment of Viral Pneumonia in Adults
The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia
- Conditions
- Viral Pneumonia, Nitric Oxide, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04606407
- Testing
- LungFit™
- Where
- 3 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Beyond Air Inc.
Sleep Apnea, Obstructive
Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP)
The purpose of this engineering trial is to develop and validate an algorithm that will deliver Paced Breathing as a ramp feature to obstructive sleep apnea (OSA) subjects using Continuous Positive Airway Pressure (CPAP) therapy.
- Trial name
- PBSW (NCT01031914)
- Testing
- Paced Breathing
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Philips Respironics
Cancer, Breakthrough Cancer Pain
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control.
- Trial name
- REBORN (NCT03564548)
- Testing
- PPP001, Morphine sulfate or Hydromorphone or Oxycodone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tetra Bio-Pharma
Pneumonia, Bacterial
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP).
- Trial name
- NCT02459158
- Testing
- ME1100 inhalation solution
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.
- Trial name
- NCT06091579
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00793624
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 93 sites in Argentina, Brazil and 18 more
- Volunteers
- 906 people
- Sponsor
- Boehringer Ingelheim
Abuse Liability of Staccato Alprazolam
Staccato Alprazolam Abuse Liability
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
- Trial name
- NCT00603980
- Testing
- Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Nova Pneuma Inc.
Bronchiectasis
High Dose Inhaled Mannitol Study
This study is to investigate the safety and tolerability of high doses of inhaled mannitol in subjects with bronchiectasis to further direct development of an improved drug delivery system.
- Trial name
- NCT01076491
- Testing
- mannitol
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Syntara
Asthma
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma
- Trial name
- NCT00252824
- Testing
- Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
- Where
- 53 sites in Chile, Croatia and 8 more
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.